Ep 151 - How Anika Therapeutics is using M&A and R&D to evolve into a global joint preservation business

In this episode, Cheryl R. Blanchard, Ph.D., CEO of Anika Therapeutics, explains how the company is morphing from a biomaterials into a joint preservation business. In an interview with Tom Salemi, editorial director of DeviceTalks, Blanchard points to collaboration she had with biomedical greats over her career, including a formative connection with Ray Elliott, the former CEO of Zimmer. Today, through sizable M&A and internal development, Anika is building a portfolio of ortho biomaterials and new joints that gives is more shots on net. Blanchard explains how Anika’s opportunity has grown its market opportunity from $1 billion to $8 billion. Chris Newmarker, executive editor of life sciences, brings this week’s Newmarker’s Newsmakers bringing news from Neuralink, Abbott, Cala Health, Cue Health, Medtronic, and Zoll Medical. Senior Editor Danielle Kirsh also visits to introduce DeviceTalks Weekly listeners to the new Fast Five Podcast, a daily podcast highlighting the biggest news in medtech. You can subscribe to the MassDevice Fast Five on any major podcast application. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network to receive future episodes of this podcast as well as Boston Scientific Talks, IntuitiveTalks, and StrykerTalks.

There are no comments yet.

Please log in to write the first comment.